1. Mobilizing phospholipids on tumor plasma membrane implicates phosphatidylserine externalization blockade for cancer immunotherapy.
- Author
-
Wang W, Wu S, Cen Z, Zhang Y, Chen Y, Huang Y, Cillo AR, Prokopec JS, Quarato G, Vignali DAA, Stewart-Ornstein J, Li S, Lu B, and Gong YN
- Subjects
- Humans, Phospholipids metabolism, Cell Membrane metabolism, Apoptosis physiology, Immunotherapy, Phosphatidylserines metabolism, Neoplasms therapy, Neoplasms metabolism
- Abstract
In "healthy" tumor cells, phosphatidylserine (PS) is predominately localized in the inner plasma membrane leaflet. During apoptosis, PS relocates to the outer leaflet. Herein, we established PS
out tumor models with tumor cells lacking PS flippase component CDC50A, constantly exposing PS but alive. PSout tumors developed bigger than wild-type (WT) tumors, featuring M2 polarized tumor-associated macrophages (TAMs) and fewer tumor-antigen-specific T cells. The PS receptor TIM-3 is responsible for PS recognition. Employing an opposite tumor model, PSin , with tumor cells lacking the PS scramblase Xkr8 and unable to expose PS during otherwise normal apoptosis, we find that the accumulated apoptotic tumor cells produce and release cyclic GAMP (cGAMP) to immune cells to activate the STING pathway, leading to TAM M1 polarization, suppressed interleukin (IL)-10 secretion, and natural killer (NK) cell cytotoxicity. Silencing Xkr8 in vivo by either short hairpin RNA (shRNA) or small interfering RNA (siRNA) to achieve a PS externalization blockade provides robust therapeutic anti-tumor efficiency., Competing Interests: Declaration of interests D.A.A.V. is cofounder and stockholder of Novasenta, Potenza, Tizona, and Trishula; stock holder of Oncorus, Werewolf, and Apeximmune; has patents licensed and royalties from Astellas, BMS, and Novasenta; is a scientific advisory board member of Tizona, Werewolf, F-Star, Bicara, Apeximmune, and T7/Imreg Bio; is a consultant for Astellas, BMS, Almirall, Incyte, G1 Therapeutics, and Inzen Therapeutics; and obtained research funding from BMS, Astellas, and Novasenta. A.R.C. is a consultant for AboundBio. All other authors declare no competing interests., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF